Channing Paller
Johns Hopkins University · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · SKCCC at Johns Hopkins
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Channing Paller as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:29 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05501548 · Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Prostate Cancer, Castration-resistant Prostate Cancer · principal investigator
- N/ANCT04995198 · PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment EffectivenessProstate Cancer Clinical Trials Consortium · recruiting · Prostate Cancer · principal investigator
- Ph3NCT03535675 · Muscadine Plus (MPX) In Men With Prostate CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Adenocarcinoma of the Prostate · principal investigator
- Ph1NCT03051477 · Trial of Mistletoe Extract in Patients With Advanced Solid TumorsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Solid Tumor · principal investigator
- Ph2NCT02516670 · Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · terminated · Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer · principal investigator
- Ph2NCT02452008 · Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · Prostate Cancer · principal investigator
- N/ANCT02370836 · Evaluating the Effects of Psycho-oncological Education on Distress and Quality of Life in Solid Tumor Cancer PatientsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Quality of Life · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- The Society for Integrative Oncology (SIO) 17th International Conference, "The Science of Living Well With Cancer"R13CA254452 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2020 · $15,000 awarded in 2020Same name and institution; not confirmed by an ID
- Overcoming drug resistance in metastatic castration resistant prostate cancer with a novel combination of TGF-beta inhibition and enzalutamideK23CA197526 · NCI · JOHNS HOPKINS UNIVERSITY · fiscal years 2016 to 2018 · $177,120 awarded in 2018Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Chemical and Structural BiologyP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI James M. Berger · fiscal years 2013 to 2026Named on NCT02516670
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:29 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.JAMA Oncol · 2020988 citationsRCR 46.6
- Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.Lancet Oncol · 2018156 citationsRCR 4.8
- TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.J Clin Oncol · 2021122 citationsRCR 6.0
- A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.Prostate Cancer Prostatic Dis · 2013112 citationsRCR 4.3
- 103 citationsRCR 4.1
- A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).BMC Cancer · 201790 citationsRCR 2.9
- 71 citationsRCR 3.3
- Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.Prostate · 201666 citationsRCR 1.8
- Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).Clin Cancer Res · 202448 citationsRCR 5.1
- Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.Nat Commun · 202444 citationsRCR 5.3